About Guangzhou Baiyunshan Pharmaceutical Holdings Co Ltd
Guangzhou Baiyunshan Pharmaceutical Holdings is a Chinese healthcare group based in Guangzhou. It develops and makes traditional Chinese medicines, over-the-counter remedies and modern pharmaceutical products, and it also produces herbal drinks and personal care items sold to consumers. The company runs a distribution and retail network that supplies hospitals, clinics and pharmacies across China, and it markets its branded medicines and consumer health products to households through retail channels.
Guangzhou Baiyunshan Pharmaceutical Holdings Co Ltd trades under the code 600332 on the Shanghai Stock Exchange in China, with its price quoted in Chinese yuan (CNY). Our dividend records, which start in 2019, show payments in 5 different calendar years. The Market X-Ray on this page is price-based and compares it with other stocks on the same exchange; it does not measure how healthy the business is.
The first paragraph was written with AI from general knowledge about the company and checked automatically; the second comes from our own data. It can contain mistakes: check the company's own website and filings before relying on it.
Market X-Ray · price-based
Fair price profile
Ranks #557 of 2278 on the Shanghai Stock Exchange · confidence High
What this score is, and is not
It describes how this stock has traded: trend, momentum, risk, liquidity and dividends, each ranked against the other stocks on its own exchange. It does not measure how healthy or cheap the business is. That fundamental X-Ray needs financial statements, which we do not have for China yet.
TrendFair
59/100
Mixed trend against its averages.
See the numbers →
Above 200-day average-10.3%
From 52-week high-25.9%
MomentumWeak
41/100
Lagging most stocks on this exchange.
See the numbers →
3-month return-8.1%
6-month return-11.6%
12-month, skipping last month-21.6%
Risk (lower is better)Strong
92/100
Calmer than most: low volatility and shallow drawdowns.
See the numbers →
Volatility (1 year)17.8%
Worst drawdown (1 year)-29.2%
LiquidityFair
58/100
Moderate trading activity.
See the numbers →
Avg daily value traded178.04M CNY
Zero-volume days0.0%
IncomeNone
–/100
Pays no dividend.
See the numbers →
Years with dividends2
Price-based X-Ray. The fundamental X-Ray (financial health, valuation, growth, fair value) is available for US stocks today. It will follow for China when fundamentals data for this market is added. All China stocks.
52-wk range 19.30 – 27.50Daily closes, split-adjusted
Signals
50-day average20.36
200-day average22.60
Golden/death cross (60d)None
New 52-week highNo
Bullish RSI divergenceNo
Average daily range (ATR)0.29
Technical summary
Daily
Bearish
5 bullish · 1 neutral · 10 bearish
Weekly
Strongly bearish
2 bullish · 1 neutral · 9 bearish
Monthly
Strongly bearish
0 bullish · 1 neutral · 7 bearish
Moving averages (daily)
SMA 10
19.89
Bullish
EMA 10
19.93
Bullish
SMA 20
19.73
Bullish
EMA 20
19.90
Bullish
SMA 50
20.36
Bearish
EMA 50
20.29
Bearish
SMA 100
20.87
Bearish
EMA 100
21.00
Bearish
SMA 200
22.60
Bearish
EMA 200
22.27
Bearish
Oscillators (daily)
RSI (14)
57.33
Neutral
MACD (12, 26)
-0.05
Bearish
Momentum (12)
3.05
Bullish
Stochastic %K (14)
97.92
Bearish
Williams %R (14)
-2.08
Bearish
CCI (20)
144.3
Bearish
Pivot points (classic, last session)
S3
19.49
S2
19.66
S1
19.96
Pivot
20.13
R1
20.43
R2
20.60
R3
20.90
Signals describe what the chart is doing, not what to do. Moving averages: price above the average is bullish. Oscillators use the usual thresholds (RSI 30/70, Stochastic 20/80, CCI ±100, Williams %R −80/−20; MACD and momentum above zero are bullish). Weekly and monthly views use closing prices only.
Dividends
Paid, last 12 months
0.00 CNY
Yield on today's price
–
Frequency
None in the last year
Next ex-dividend date
Not announced
Ex-dividend date
Amount per share
16 Jun 2023
0.7320
17 Jun 2022
0.6870
21 Jun 2021
0.5380
13 Jul 2020
0.5890
11 Jul 2019
0.4240
Ex-dividend dates and amounts from EODHD. Shown as declared, before tax.
Prices are end-of-day closes in CNY. Educational only, not financial advice.